Apollomics Inc. Class A Ordinary Shares (APLM) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Apollomics Inc. Class A Ordinary Shares (APLM) has a cash flow conversion efficiency ratio of -2.622x as of March 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-12.76 Million) by net assets ($4.86 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Apollomics Inc. Class A Ordinary Shares market capitalisation for the company's overall valuation and market capitalisation.
Apollomics Inc. Class A Ordinary Shares - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Apollomics Inc. Class A Ordinary Shares's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Apollomics Inc. Class A Ordinary Shares Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Apollomics Inc. Class A Ordinary Shares ranked by their cash flow conversion efficiency. See Apollomics Inc. Class A Ordinary Shares (APLM) debt coverage ratio to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Yuyu Pharma Inc
KO:000227
|
0.006x |
|
B&M European Value Retail SA
LSE:BME
|
0.576x |
|
Tong-Hwa Synthetic Fiber Co Ltd
TW:1418
|
-0.051x |
|
IFCA MSC Bhd
KLSE:0023
|
-0.058x |
|
SBF AG
F:CY1K
|
N/A |
|
Tate & Lyle PLC
LSE:TATE
|
0.074x |
|
Next Science Ltd
AU:NXS
|
2.498x |
|
Briacell Therapeutics Corp
NASDAQ:BCTX
|
-0.302x |
Annual Cash Flow Conversion Efficiency for Apollomics Inc. Class A Ordinary Shares (2019–2025)
The table below shows the annual cash flow conversion efficiency of Apollomics Inc. Class A Ordinary Shares from 2019 to 2025. View Apollomics Inc. Class A Ordinary Shares stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-3.19 Million | $-10.37 Million | 3.253x | +155.04% |
| 2024-12-31 | $4.86 Million | $-28.74 Million | -5.909x | -463.92% |
| 2023-12-31 | $41.23 Million | $-43.21 Million | -1.048x | -1196.54% |
| 2022-12-31 | $-448.12 Million | $-42.82 Million | 0.096x | -53.03% |
| 2021-12-31 | $-212.86 Million | $-43.31 Million | 0.203x | -27.04% |
| 2020-12-31 | $-127.93 Million | $-35.68 Million | 0.279x | -22.82% |
| 2019-12-31 | $-60.72 Million | $-21.94 Million | 0.361x | -- |
About Apollomics Inc. Class A Ordinary Shares
Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. The company's products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung… Read more